1 The clearance of dihydroartemisinin (DHA) in control and malaria-infected (MI) rats was investigated using the isolated perfused rat liver (IPRL) model and hepatic microsomal studies. 2 In the recirculating IPRL, clearance of DHA was reduced from a mean (s.d.) of 8.2+1.8 ml min 71 in controls (n=8) to 6.0+1.0 ml min 71 in MI (n=8; P50.01). Clearance in control livers was similar to the perfusion¯ow rate, suggesting a high hepatic extraction ratio for DHA. 3 Single-pass IPRL studies in controls (n=8) showed that DHA bioavailability at 1.3, 8 and 38 mM was 0.026+0.020, 0.043+0.025 and 0.14+0.06, respectively (P50.001 for 8 mM vs 38 mM). In MI livers (n=5), DHA bioavailability at 8 and 38 mM was 0.18+0.07 and 0.40+0.08, respectively (P=0.002). Bioavailability was higher in the MI group than in controls (P=0.01 at 8 mM and P50.001 at 38 mM). DHA-glucuronide was the sole biliary metabolite. 4 Hepatic microsomal studies of DHA-glucuronide formation showed a signi®cantly lower V max , but no signi®cant change in K m , in MI compared to control livers (n=6). Intrinsic metabolic clearance (V max /K m ) was higher in control than in MI livers (5.2+1.3 and 2.5+1.4 ml min 71 mg 71 , respectively; P=0.006). 5 These studies demonstrate that DHA has a high, concentration-dependent hepatic extraction ratio that is reduced by 20 ± 30% in the P. berghei rodent malaria model. The impaired hepatic clearance of DHA in MI is attributable to a reduction in intrinsic metabolic clearance.